Related Experiment Video
Updated: Aug 16, 2025
09:25
Methods to Evaluate Cytotoxicity and Immunosuppression of Combustible Tobacco Product Preparations
Published on: January 10, 2015
11.5K
Advancing Tobacco Cessation in LMICs.
Abhishek Shankar1, Mark Parascandola2, Pirabu Sakthivel3
1Department of Radiation Oncology, All India Institute of Medical Sciences, Patna 801507, India.
Current Oncology (Toronto, Ont.)
|December 22, 2022
Summary
Tobacco use causes over 8 million deaths annually, disproportionately affecting low- and middle-income countries (LMICs). Tailored cessation strategies and local research capacity are crucial for effective tobacco control in these regions.
Area of Science:
- Public Health
- Global Health
- Tobacco Control
Background:
- Tobacco use results in over 8 million global deaths annually.
- Low- and middle-income countries (LMICs) bear a significant burden, with over 80% of tobacco users residing there.
- Tobacco control progress lags in LMICs, with limited implementation of cessation programs.
Purpose of the Study:
- To review existing evidence on tobacco cessation interventions in LMICs.
- To identify key challenges and research gaps in tobacco cessation within LMICs.
- To emphasize the need for context-specific strategies and capacity building.
Main Methods:
- Literature review of tobacco cessation interventions.
- Analysis of evidence applicability in LMIC contexts.
- Identification of implementation barriers and research needs.
Main Results:
- Evidence for cessation interventions largely originates from high-income countries.
- Limited resources and training hinder cessation program effectiveness in LMICs.
- Significant research and implementation gaps exist for tailored interventions.
Conclusions:
- Locally relevant research and implementation science are essential for LMICs.
- Capacity building is needed to develop and deploy effective, tailored tobacco cessation strategies.
- Addressing the growing tobacco burden in LMICs requires context-specific approaches.
Related Concept Videos
01:29Chronic Obstructive Pulmonary Disease-V: Management
2.7K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.7K
01:26COPD: Management Using Bronchodilators and Corticosteroids
275
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
275
01:26Atherosclerosis III: Management
19
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
19
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
747
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
747
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
2.9K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
2.9K
01:22Chronic Obstructive Pulmonary Disease
1.4K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
1.4K